3. References

  1. IBM Micromedex® DRUGDEX® (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: https://www-micromedexsolutions-com.libproxy.uthscsa.edu/ (cited: May 30, 2023).
  2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2023. Available at: http://clinicalpharmacology-ip.com.ezproxy.lib.utexas.edu/. Accessed May 30, 2023.
  3. Mecasermin [rDnA origin] injection (Increlex®) package insert. Ipsen Biopharmaceuticals, Inc., May 2020.
  4. Chernausek SD, Backeljauw PF, Frane J, et al for the GH Insensitivity Syndrome Collaborative Group. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab. 2007;92(3):902-10.
  5. Bright GM, Mendoza JR, Rosenfeld RG. Recombinant human insulin-like growth factor-1 treatment: ready for primetime. Endocrinol Metab Clin N Am. 2009;38:625-38.
  6. Midyett LK, Rogol AD, Van Meter QL, et al. Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels:  first-year results from a randomized clinical trial. J Clin Endocrinol Metab.  2010;95: 611–9.
  7. Cohen J, Blethen S, Kuntze J, et al. Managing the child with severe primary insulin-like growth factor-1 deficiency (IGFD): IGFD diagnosis and management. Drugs R D. 2014;14:25-9.